[go: up one dir, main page]

EP1387683A1 - Novel salt and crystalline forms of (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinoline - Google Patents

Novel salt and crystalline forms of (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinoline

Info

Publication number
EP1387683A1
EP1387683A1 EP02723495A EP02723495A EP1387683A1 EP 1387683 A1 EP1387683 A1 EP 1387683A1 EP 02723495 A EP02723495 A EP 02723495A EP 02723495 A EP02723495 A EP 02723495A EP 1387683 A1 EP1387683 A1 EP 1387683A1
Authority
EP
European Patent Office
Prior art keywords
drug
piperazin
treatment
hydroxypropoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02723495A
Other languages
German (de)
French (fr)
Other versions
EP1387683B1 (en
Inventor
Julie Kay Bush
Susan Marie Reutzel-Edens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1387683A1 publication Critical patent/EP1387683A1/en
Application granted granted Critical
Publication of EP1387683B1 publication Critical patent/EP1387683B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Definitions

  • Drug resistance is the name given to the circumstance when a disease does not respond to a treatment drug or drugs. Drug resistance can be either intrinsic, which means the disease has never been responsive to the drug(s), or it can be acquired, which means the disease ceases responding to a drug or drugs to which the disease had previously been responsive. Multidrug resistance is a specific type of drug resistance that is characterized by cross- resistance of a disease to more than one functionally and/or structurally unrelated drugs.
  • Multidrug resistance in the field of cancer is discussed in greater detail in Kuzmich and Tew, "Detoxification Mechanisms and Tumor Cell Resistance to Anticancer Drugs,” particularly section VII “The Multidrug-Resistant Phenotype (MDR),” Medical Research Reviews, Vol. 11, No. 2, 185-217, particularly 208-213 (1991); and in Georges, Sharom and Ling, “Multidrug Resistance and Chemosensitization: Therapeutic Implications for Cancer Chemotherapy,” Advances in Pharmacology, Vol. 21, 185-220 (1990).
  • Treatment of drug and multidrug resistance typically involves the coadministration of a drug suitable for treatment of the disease and a compound which acts through various mechanisms to cause the drug suitable for treatment of a disease to begin and/or continue to function as a therapeutic agent.
  • U.S. patent 5,654,304 ('304), incorporated by reference herein, discloses a series of 10,11 -(optionally substituted)methanodibenzosuberane derivatives useful in enhancing the efficacy of existing cancer chemotherapeutics and for treating multidrug resistance.
  • the 2.5 salt and Form E and Form HI offer advantages to formulation and analytical development because they sorb less water overall over a wide range of relative humidity as compared to the trihydrochloride salt and crystal; they are thermodynamically more stable than the trihydrochloride salt and crystal; and they do not incorporate organic solvents as readily as the trihydrochloride salt and crystal.
  • the present invention provides a novel composition of matter: (2R)-anti-5- ⁇ 3-[4-
  • the present invention further provides a novel hydrate crystal form ' of (2R)- «t/-5- ⁇ 3-[4-(l 0, 11 -difluoromethanodibenzosuber-5-yl)piperazin-l -yl]-2- hydroxypropoxy ⁇ quinoline 2.5 hydrochloride ("Form II”), having an X-ray diffraction pattern comprising the following peaks: 6.0, 9.1, 10.8, 11.6, 12.0, 13.1, 13.6, 24.1, and 26.2 ⁇ 0.2° in 2 ⁇ when obtained with a copper radiation source.
  • the present invention further provides a novel hydrate crystal form of (2R)- ⁇ ntz-5- ⁇ 3-[4-(10,l l-difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2- hydroxypropoxy ⁇ quinoline 2.5 hydrochloride ("Form II"), having a solid-state C NMR spectrum comprising isotropic peaks at the following chemical shifts: 29.9, 50.1, 55.3, 62.0, 66.5, 72.0, 75.8, 104.8, 107.5, 108.2, 109.1, 110.2, 112.0, 118.4, 119.5, 120.1, 123.1, 128.7, 131.1, 133.0, 134.8, 136.4, 136.9, 139.9, 140.0, 142.3, 144.5, 146.6, 149.0, 144.2, 153.0 and 153.6 ppm.
  • the present invention further provides a novel hydrate crystal form of (2R)- «tt-5-
  • Form HI ⁇ 3-[4-(l 0, 11 -difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2- hydroxypropoxy ⁇ quinoline 2.5 hydrochloride
  • Form HI X-ray diffraction pattern comprising the following peaks: 8.2, 10.4, 11.9, 17.2, and 23.0 ⁇ 0.2° in 20 when obtained with a copper radiation source.
  • the present invention further provides a novel hydrate crystal form of (2R)- ⁇ Rtz-5-
  • the present invention further provides a method of treatment for a drug resistant disease comprising coadministering to a mammal in need thereof a resistance modulating amount of the 2.5 hydrochloride salt, Form H, or Form HI and an effective amount of a treatment drug for said drug resistant disease.
  • the present invention further provides a method of treatment for a multidrug resistant disease comprising coadministering to a mammal in need thereof a multidrug resistance modulating amount of the 2.5 hydrochloride salt, Form H, or Form HI and an effective amount of a treatment drug for said multidrug resistant disease.
  • the present invention further provides a method for enhancing bioavailability of a drug to the brain, comprising coadministering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 hydrochloride salt, Form H, or Form HI sufficient enough to allow said drug to cross the blood-brain barrier and enter the brain.
  • the present invention further provides a method for enhancing oral bioavailability of a drug comprising administering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 hydrochloride salt, Form H, or Form HI sufficient enough to allow said drug to be transported across the gastrointestinal tract and enter the bloodstream.
  • Figure 1 depicts a representative XRD pattern of Form II.
  • Figure 2 depicts a representative XRD pattern of Form III.
  • Figure 3 is a representative solid state C NMR spectrum of Form II.
  • Figure 4 is a representative solid state C NMR spectrum of Form III.
  • the term "pharmaceutical” when used as an adjective means substantially non-toxic to -living organisms.
  • the term “pharmaceutical salt” as used herein refers to salts of the compounds of formula I which are substantially non-toxic to living organisms. See, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., "Pharmaceutical Salts", J Pharm. Sci., 66:1, 1977.
  • Typical pharmaceutical salts include those salts prepared by reaction of the compounds of formula I with an inorganic or organic acid or base. Such salts are known as acid addition or base addition salts respectively.
  • These pharmaceutical salts frequently have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
  • cancer therapeutic agent refers to compounds, which have an anticancer therapeutic effect.
  • Such compounds are non-antimetabolites such as anthracycline group antibiotics, e.g. adriamycin, daunomycin, doxorubicin, or acrasinomycin A; actinomycin group antibiotics, e.g. actimomycin C or D; chromomycin group antibiotics, e.g. mithramycin or toyomycin; vincoalkaloids, e.g. vincristine, or vinblastine; meitansins; podophyllotoxin derivatives, e.g. VP16-213; homoharintonin; angwindin; bruceantin; neocarcinostatin; anthromycin; mitomycin C; and cisplatin. Additional cancer therapeutic agents may be found in the medical literature, for example,
  • bioavailability refers to the degree and rate at which a drug, or other substance, becomes available to a target tissue within a mammal.
  • coadministering means a disease treatment drug and the 2.5 salt,
  • Form H or Form HI are given to a mammal.
  • Form HI are given to a mammal simultaneously or at different times.
  • drug resistance refers to the circumstance when a disease does not respond to a treatment drug or drugs. Drug resistance can be either intrinsic, which means the disease has never been responsive to the drug or drugs, or it can be acquired, which means the disease ceases responding to a drug or drugs that the disease had previously responded to.
  • Multidrug resistance means a specific type of drug resistance characterized by cross-resistance of a disease to more than one functionally and/or structurally unrelated drugs. Multidrug resistance can be either intrinsic or acquired.
  • Forms II and HI offer significant advantages over the prior art compound Form I.
  • Forms H and HI have more favorable moisture sorption characteristics, i.e. a flatter moisture sorption profile, as they sorb less water overall over a wide range of relative humidity;
  • Forms H and HI are thermodynamically more stable than Form I, with Form H being the most stable in organic solutions and in the solid state at ambient temperature/relative humidity and Form HI being the most stable in aqueous and acidic media;
  • Forms H and HI do not incorporate organic solvents as readily as Form I, eliminating the need for lengthy humidif ⁇ cation steps which are required to remove residual organic solvents from the Form I lattice; and the crystal morphology of Forms H and HI are superior to Form I for the purpose of bulk and pharmaceutical processing.
  • Forms H and IH have a distinctly different morphology, which has been shown to be easier to filter than the rod-shaped crystals of Form I.
  • a number of methods are available to characterize crystalline forms of organic compounds. Among these methods are differential scanning calorimetry, solid state NMR spectrometry, infra-red spectroscopy, and x-ray powder diffraction.
  • the x-ray powder diffraction pattern in particular, is very useful for distinguishing between different crystalline forms of a compound.
  • X-ray powder diffraction analysis can be readily performed as follows. After lightly grinding the sample with an agate mortar and pestle, the sample is loaded into a sample holder for the x-ray powder diffraction measurement.
  • Forms H and HI have typical XRD patterns as represented in Tables 1 and 2, respectively, with peaks which have typical relative intensities (I/I 0 ) at the following 2 ⁇ values, where ⁇ is the incident angle of the X-ray beam..
  • the error of measurement is +/- 0.2° in 2 ⁇ .
  • X-ray peaks with I I 0 of 5% or greater were reported in Tables 1 and 2. The cutoff was chosen arbitrarily. -1-
  • the relative intensities of the diffraction peaks may vary due to a number of factors, including the effects of preferred orientation which result from a particular crystal morphology, and particle size. Where the effects of preferred orientation and or particle size are present, peak intensities (that is, the I/ o value) are altered, but the characteristic peak positions of the polymorph are unchanged. See, e.g., The United States Pharmacopoeia #23, National Formulary #18, pages 1843-1844, 1995.
  • the effects of preferred orientation can be greatly reduced using a sample that is prepared in a manner that minimizes these effects, such as the use of a well ground sample.
  • Form H may be characterized as having an X-ray diffraction pattern which comprises peaks at the following 2 ⁇ values: 6.0, 9.1, 10.8, 11.6, 12.0, 13.1, 13.6, 24.1, and 26.2 + 0.2° when measured using a copper radiation source.
  • Form HI may be characterized as having an X-ray diffraction pattern which comprises peaks at the following 2 ⁇ values: 8.2, 10.4, 11.9, 17.2, and 23.0 ⁇ 0.2° when measured using a copper radiation source.
  • Form H and Form HI may also be characterized by solid state NMR spectroscopy.
  • Form H has a solid-state 13 C NMR spectrum comprised of isotropic peaks at the following chemical shifts: 29.9, 50.1, 55.3, 62.0, 66.5, 72.0, 75.8, 104.8, 107.5, 108.2, 109.1, 110.2, 112.0, 118.4, 119.5, 120.1, 123.1, 128.7, 131.1, 133.0, 134.8, 136.4, 136.9, 139.9, 140.0, 142.3, 144.5, 146.6, 149.0, 144.2, 153.0 and 153.6 ppm.
  • Form HI has a solid-state 13 C NMR spectrum comprised of isotropic peaks at the following chemical shifts: 30.3, 50.4, 59.1, 63.2, 72.8, 77.2, 109.1, 110.2, 112.2, 112.8,
  • Form H and Form HI may also be characterized by the molar ratio of the chloride anion in the present invention.
  • the determination can be analyzed by ion chromatography using a Dionex HPIC-AS4 with a Dionex Anion AMMS-1 micro-membrane suppressor.
  • a standard stock solution of anhydrous sodium chloride (16.5 mg/100 ml)
  • standard concentration ranges form 50-150% of the chloride anion.
  • the sample was prepared in a lmg/ml solution of purified water. Sonication for 10-15 min. and filtration was applied if insolubility was seen. A typical sample concentration of 0. lmg/ml was used.
  • the HPLC analysis conditions were conducted at 2 ml/min at room temperature with a run time of 780 sec. An approximate retention time of the chloride anion is about 115 sec.
  • the molar percent of the anion was calculated by the following data analysis. A least squares calibration curve of the standard peak versus the standard peak concentration ( ⁇ g/ml).
  • % anion ( ⁇ g anion/mL found*) [dilution] (100%) mg (samp, weight) 11000 // gj *from calibration curve
  • Form H may be prepared by slurry conversion of Form HI under controlled conditions. It is understood that the present process can utilize (2R)- ⁇ «tz-5- ⁇ 3-[4-(10,l l-difluoromethanodibenzosuber-5- yl)piperazin-l-yl]-2-hydroxypropoxy ⁇ quinoline trihydrochloride regardless of its hydration state or crystalline state.
  • Form H or HI can be isolated from the crystallization solution by filtration, if desired after cooling, and washed and dried. If desired, either Form H or HI maybe further crystallized using similar conditions for crystallization, to those described below.
  • the present invention is further illustrated by the following examples and preparations.
  • Example 1 Form HI Suspend (2R)- ⁇ ntt-l-[4-(10,l l-difluoromethano-10,1 l-dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-piperazin-l-yl]-3-quinolin-5-yloxy)-propan-2-ol trihydrochloride (502 mg) in 3 A EtOH (10 mL). Heat to reflux and add H 2 O (5 mL) to dissolve the solids. Remove the heat source and add EtOAc (75 mL) to the warm solution. Isolate by vacuum filtration, wash with EtOAc (2 mL), and air-dry in a B ⁇ chner funnel under an air stream.
  • Example 3 Form H Suspend 7.52 g of (2R)- ⁇ ntt-l-[4-(10,l l-difluoromethano-10,1 l-dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-piperazin-l-yl]-3-quinolin-5-yloxy)-propan-2-ol trihydrochloride in 6: 1 v/v tert-butanol- water (75 mL) and heat under reflux for 30 minutes to dissolve the solids. Turn the heat source off, and allow the solution to slowly cool to room temperature.
  • Example 5 Form H Dry Form HI at 50-70°C in a convection oven.
  • the present invention further provides a method of treatment for a drug resistant disease comprising coadministering to a mammal in need thereof a resistance modulating amount of the 2.5 salt, Form H, or Form HI and an effective amount of a treatment drug for said drug resistant disease.
  • a treatment drug for said drug resistant disease is cancer.
  • the treatment drug is a cancer chemotherapeutic agent.
  • the present invention further provides a method of treatment for a multidrug resistant disease comprising coadministering to a mammal in need thereof a multidrug resistance modulating amount of the 2.5 salt, Form H, or Form HI and an effective amount of a treatment drug for said multidrug resistant disease.
  • the treatment drug is a cancer chemotherapeutic agent.
  • the present invention further provides a method for enhancing bioavailability of a pharmaceutically active agent to the brain, comprising coadministering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 salt, Form H, or Form HI sufficient enough to allow said drug to cross the blood-brain barrier and enter the brain.
  • the active agent is an HIV protease inhibitor.
  • protease inhibitors contemplated by the present invention are NELFINAVIR, which is preferably administered as the mesylate salt at 750 mg three times per day (U.S. Patent No. 5,484,926, herein incorporated by reference); RITONAVIR, which is preferably administered at 600 mg twice daily (U.S. Patent No.
  • SAQUINAVIR which is preferably administered at the mesylate salt at 1,200 mg three times per day
  • IND AVTR which is preferably administered as the sulfate salt at 800 mg three times per day
  • AMPRENAVIR which is preferably administered at 1,200 mg twice daily (U.S. Patent No. 5,585,397, herein incorporated by reference).
  • protease inhibitors' administration to a patient may vary from the preferred.
  • the present invention further provides the use of the 2.5 salt, Form H, or Form HI in combination with an effective amount of a treatment drug, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a drug resistant disease.
  • a treatment drug or a pharmaceutically acceptable salt thereof
  • the disease is cancer.
  • the treatment drug is a cancer chemotherapeutic agent.
  • the invention further provides the use of the 2.5 salt, Form H, or Form HI in combination with an effective amount of a treatment drug, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a multidrug resistant disease.
  • the treatment drug is a cancer chemotherapeutic agent.
  • the present invention further provides the use of the 2.5 salt, Form H, or Form HI in combination with a pharmaceutically active agent, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for enhancing bioavailability of the pharmaceutically active agent to the brain, comprising coadministering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 salt, Form H, or
  • the active agent is an HIV protease inhibitor.
  • the present invention relates to a pharmaceutical formulation comprising the 2.5 salt, Form H, or Form HI; one or more pharmaceutical carriers, diluents, or excipients; and optionally a treatment drug.
  • the 2.5 salt, Form H, or Form HI is usually administered in the form of pharmaceutical compositions.
  • These compositions can be administered by a variety of routes including oral, rectal, transdermal, and intranasal.
  • Such compositions are prepared in a manner well known in the pharmaceutical art and comprise the 2.5 salt, Form H, or Form HI.
  • substantially pure refers to the crystal phase purity of Form H or HI. In practice we have found that small amounts of other crystalline forms do not adversely affect the advantageous properties of Form H or HI. According to the present invention substantially pure refers to Form H or HI which is greater than 90%, preferably greater than 95% of the total crystalline material.
  • compositions which contain the 2.5 salt, Form H, or Form HI (referred to as "active ingredient” herein below) associated with pharmaceutically acceptable carriers.
  • active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier, which can be in the form of a capsule, sachet, paper or other container.
  • excipient serves as a diluent, it can be a solid or semi-solid, which acts as a vehicle, carrier, or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, emulsions, aerosols, ointments containing, for example, up to 10% by weight of the active compound, tablet, soft and hard gelatin capsules, suppositories, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, algmates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 mg to about 30 mg, of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the 2.5 salt, Form H, or Form HI is employed at no more than about 20 weight percent of the pharmaceutical composition, more preferably no more than about 15 weight percent, with the balance being pharmaceutically inert carrier(s).
  • the 2.5 salt, Form H, or Form HI is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
  • pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can separated by enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions for inhalation or insufflation include liquids, suspensions, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices, which deliver the formulation in an appropriate manner.
  • transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent
  • patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • Indirect techniques usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs.
  • Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier.
  • the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions, which can transiently open the blood-brain barrier.
  • the 2.5 salt, Form H, or Form HI is suitable for use in a variety of drug delivery systems described above. Additionally, in order to enhance the in vivo serum half-life of the present compound, it may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques maybe employed which provide an extended serum half-life of the compounds. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., U.S. Patent Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference.
  • the amount of the 2.5 salt, Form H, or Form HI administered to the patient will vary depending upon the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like.
  • compositions are administered to a patient already suffering from cancer in an amount sufficient to at least partially arrest further onset of the symptoms of the disease and its complications.
  • An amount adequate to accomplish this is defined as "therapeutically effective dose.” Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the degree or severity of the disease state in the patient, the age, weight and general condition of the patient, and the like.
  • the 2.5 salt, Form H, or Form HI is administered at dosages ranging from about 1 to about 500 mg/kg/day.
  • the present invention provides a process for preparing the Form H or Form HI which comprises crystallizing (2R)- ⁇ «tt-5- ⁇ 3-[4-(10,l l-difluoromethanodibenzosuber-5- yl)piperazin- 1 -yl] -2-hydroxypropoxy ⁇ quinoline trihydrochloride from a solution of water and a water miscible solvent under conditions which yield Form H or HI.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

The present invention provides methods of treating leukemia comprising administration of a resistance modulating amount of a compound having the formula (2r)-anti-5-{3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline 2.5 hydrochloride.

Description

NOVEL SALT AND CRYSTALLINE FORMS OF (2R)- N77-5-{3-[4-(10,ll-
DIFLUOROMETHANODIBENZOSUBER-5-YL)PIPERAZIN-l-YL]-2-
HYDROXYPROPOXY}QUINOLINE
Among the problems faced in certain types of drug therapy, including cancer chemotherapy and malaria drug therapy, is the phenomena of resistance to treatment regimens. The resistance means, for example, that cancerous tumors that responded well initially to a particular drug or drugs, later develop a tolerance to the drug(s). Drug resistance is the name given to the circumstance when a disease does not respond to a treatment drug or drugs. Drug resistance can be either intrinsic, which means the disease has never been responsive to the drug(s), or it can be acquired, which means the disease ceases responding to a drug or drugs to which the disease had previously been responsive. Multidrug resistance is a specific type of drug resistance that is characterized by cross- resistance of a disease to more than one functionally and/or structurally unrelated drugs. Multidrug resistance in the field of cancer, is discussed in greater detail in Kuzmich and Tew, "Detoxification Mechanisms and Tumor Cell Resistance to Anticancer Drugs," particularly section VII "The Multidrug-Resistant Phenotype (MDR)," Medical Research Reviews, Vol. 11, No. 2, 185-217, particularly 208-213 (1991); and in Georges, Sharom and Ling, "Multidrug Resistance and Chemosensitization: Therapeutic Implications for Cancer Chemotherapy," Advances in Pharmacology, Vol. 21, 185-220 (1990).
Treatment of drug and multidrug resistance typically involves the coadministration of a drug suitable for treatment of the disease and a compound which acts through various mechanisms to cause the drug suitable for treatment of a disease to begin and/or continue to function as a therapeutic agent. U.S. patent 5,654,304 ('304), incorporated by reference herein, discloses a series of 10,11 -(optionally substituted)methanodibenzosuberane derivatives useful in enhancing the efficacy of existing cancer chemotherapeutics and for treating multidrug resistance. (2R)-α«tt-5-{3-[4-(10,l l-Difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2- hydroxypropoxy}quinoline trihydrochloride is disclosed in '304 and is currently under development as a pharmaceutical agent. WOOO/75121 discloses Form I, a crystalline form of(2R)- ntt-5-{3-[4-(10,ll-difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2- hydroxypropoxy} quinoline trihydrochloride.
There continues to be a need for novel salt and crystalline forms of (2R)-anti-5- {3-[4-(l 0, 11 -difluoromethanodibenzosuber-5-yl)piperazin-l -yl]-2- hydroxypropoxy} quinoline, which can be conveniently formulated for administration to patients and which are pure and highly crystalline in order to fulfill exacting pharmaceutical requirements and specifications. Preferably, such compounds will be readily formed and have favorable bulk characteristics. Examples of favorable bulk characteristics are drying times, filterability, solubility, intrinsic dissolution rate, thermal stability, and hygroscopicity. Decreased levels of organic solvents in the crystal lattice are also favorable, due in part to potential solvent toxicity to the recipient as a function of the solvent. Furthermore, the process for preparing such a compound also needs to be conveniently carried out on commercial scale.
We have now surprisingly and unexpectedly found one salt and two novel crystalline forms of (2R)-anti-5- {3-[4-(l 0, 11 -difluoromethanodibenzosuber-5- yl)piperazin-l-yl]-2-hydroxypropoxy} quinoline; (2R)-α«tt-5-{3-[4-(10,ll- difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2-hydroxypropoxy}quinoline 2.5 hydrochloride and it's crystalline forms, Form It and Form HI. The 2.5 salt and Form II and Form HI offer numerous advantages over the trihydrochloride salt and crystal. The 2.5 salt and Form E and Form HI offer advantages to formulation and analytical development because they sorb less water overall over a wide range of relative humidity as compared to the trihydrochloride salt and crystal; they are thermodynamically more stable than the trihydrochloride salt and crystal; and they do not incorporate organic solvents as readily as the trihydrochloride salt and crystal. The present invention provides a novel composition of matter: (2R)-anti-5- {3-[4-
( 10, 11 -difluoromethanodibenzosuber-5 -yl)piperazin- 1 -yl] -2-hydroxypropoxy} quinoline 2.5 hydrochloride.
The present invention further provides a novel hydrate crystal form'of (2R)- «t/-5- {3-[4-(l 0, 11 -difluoromethanodibenzosuber-5-yl)piperazin-l -yl]-2- hydroxypropoxy} quinoline 2.5 hydrochloride ("Form II"), having an X-ray diffraction pattern comprising the following peaks: 6.0, 9.1, 10.8, 11.6, 12.0, 13.1, 13.6, 24.1, and 26.2 ± 0.2° in 2Θ when obtained with a copper radiation source.
The present invention further provides a novel hydrate crystal form of (2R)-αntz-5- {3-[4-(10,l l-difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2- hydroxypropoxy} quinoline 2.5 hydrochloride ("Form II"), having a solid-state C NMR spectrum comprising isotropic peaks at the following chemical shifts: 29.9, 50.1, 55.3, 62.0, 66.5, 72.0, 75.8, 104.8, 107.5, 108.2, 109.1, 110.2, 112.0, 118.4, 119.5, 120.1, 123.1, 128.7, 131.1, 133.0, 134.8, 136.4, 136.9, 139.9, 140.0, 142.3, 144.5, 146.6, 149.0, 144.2, 153.0 and 153.6 ppm. The present invention further provides a novel hydrate crystal form of (2R)- «tt-5-
{3-[4-(l 0, 11 -difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2- hydroxypropoxy} quinoline 2.5 hydrochloride ("Form HI"), having an X-ray diffraction pattern comprising the following peaks: 8.2, 10.4, 11.9, 17.2, and 23.0 ± 0.2° in 20 when obtained with a copper radiation source. The present invention further provides a novel hydrate crystal form of (2R)-αRtz-5-
{3-[4-(10,ll-difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2- hydroxypropoxy} quinoline 2.5 hydrochloride ("Form HI"), having a solid-state 13C NMR spectrum comprising isotropic peaks at the following chemical shifts: 30.3, 50.4, 59.1, 63.2, 72.8, 77.2, 109.1, 110.2, 112.2, 112.8, 118.7, 119.5, 119.9, 121.0, 122.2, 123.0, 128.9, 130.6, 132.7, 134.0, 136.4, 140.0, 141.0, 141.8, 142.5, 143.3, 146.1, 153.1, 153.8 and 154.7 ppm.
The present invention further provides a method of treatment for a drug resistant disease comprising coadministering to a mammal in need thereof a resistance modulating amount of the 2.5 hydrochloride salt, Form H, or Form HI and an effective amount of a treatment drug for said drug resistant disease.
The present invention further provides a method of treatment for a multidrug resistant disease comprising coadministering to a mammal in need thereof a multidrug resistance modulating amount of the 2.5 hydrochloride salt, Form H, or Form HI and an effective amount of a treatment drug for said multidrug resistant disease. The present invention further provides a method for enhancing bioavailability of a drug to the brain, comprising coadministering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 hydrochloride salt, Form H, or Form HI sufficient enough to allow said drug to cross the blood-brain barrier and enter the brain.
The present invention further provides a method for enhancing oral bioavailability of a drug comprising administering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 hydrochloride salt, Form H, or Form HI sufficient enough to allow said drug to be transported across the gastrointestinal tract and enter the bloodstream.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts a representative XRD pattern of Form II. Figure 2 depicts a representative XRD pattern of Form III. Figure 3 is a representative solid state C NMR spectrum of Form II.
Figure 4 is a representative solid state C NMR spectrum of Form III.
DETAILED DESCRIPTION OF THE INVENTION
Definitions and General Parameters The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
In general, the term "pharmaceutical" when used as an adjective means substantially non-toxic to -living organisms. For example, the term "pharmaceutical salt" as used herein, refers to salts of the compounds of formula I which are substantially non-toxic to living organisms. See, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., "Pharmaceutical Salts", J Pharm. Sci., 66:1, 1977. Typical pharmaceutical salts include those salts prepared by reaction of the compounds of formula I with an inorganic or organic acid or base. Such salts are known as acid addition or base addition salts respectively. These pharmaceutical salts frequently have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
The term "cancer therapeutic agent" refers to compounds, which have an anticancer therapeutic effect. Such compounds are non-antimetabolites such as anthracycline group antibiotics, e.g. adriamycin, daunomycin, doxorubicin, or acrasinomycin A; actinomycin group antibiotics, e.g. actimomycin C or D; chromomycin group antibiotics, e.g. mithramycin or toyomycin; vincoalkaloids, e.g. vincristine, or vinblastine; meitansins; podophyllotoxin derivatives, e.g. VP16-213; homoharintonin; angwindin; bruceantin; neocarcinostatin; anthromycin; mitomycin C; and cisplatin. Additional cancer therapeutic agents may be found in the medical literature, for example,
Section XHI, "Chemotherapy of Neoplastic Diseases" in Goodman and Gilman's The
Pharmacological Basis of Therapeutics, Seventh Edition, pages 1240-1306 (1985). The term "bioavailability" refers to the degree and rate at which a drug, or other substance, becomes available to a target tissue within a mammal. The term "coadministering" means a disease treatment drug and the 2.5 salt,
Form H, or Form HI are given to a mammal. The drug and the 2.5 salt, Form H, or
Form HI are given to a mammal simultaneously or at different times.
The term "drug resistance" refers to the circumstance when a disease does not respond to a treatment drug or drugs. Drug resistance can be either intrinsic, which means the disease has never been responsive to the drug or drugs, or it can be acquired, which means the disease ceases responding to a drug or drugs that the disease had previously responded to.
"Multidrug resistance" means a specific type of drug resistance characterized by cross-resistance of a disease to more than one functionally and/or structurally unrelated drugs. Multidrug resistance can be either intrinsic or acquired.
The terms and abbreviations used herein have their normal meanings unless otherwise designated, for example, "°C" refers to degrees Celsius; "N" refers to normal or normality; "mmol" refers to millimole or millimoles; "g" refers to gram or grams; "d" refers to density, "min." refers to minutes, "mL" means milliliter or milliliters; "M" refers to molar or molarity; "HPLC" refers to high performance liquid chromatography; "mm" refers to millimeters; "cm" refers to centimeters; "nm" refers to nanometers; and "tr" refers to retention time.
Forms II and HI offer significant advantages over the prior art compound Form I. For example Forms H and HI have more favorable moisture sorption characteristics, i.e. a flatter moisture sorption profile, as they sorb less water overall over a wide range of relative humidity; Forms H and HI are thermodynamically more stable than Form I, with Form H being the most stable in organic solutions and in the solid state at ambient temperature/relative humidity and Form HI being the most stable in aqueous and acidic media; Forms H and HI do not incorporate organic solvents as readily as Form I, eliminating the need for lengthy humidifϊcation steps which are required to remove residual organic solvents from the Form I lattice; and the crystal morphology of Forms H and HI are superior to Form I for the purpose of bulk and pharmaceutical processing. Forms H and IH have a distinctly different morphology, which has been shown to be easier to filter than the rod-shaped crystals of Form I.
A number of methods are available to characterize crystalline forms of organic compounds. Among these methods are differential scanning calorimetry, solid state NMR spectrometry, infra-red spectroscopy, and x-ray powder diffraction. The x-ray powder diffraction pattern, in particular, is very useful for distinguishing between different crystalline forms of a compound.
X-ray powder diffraction analysis can be readily performed as follows. After lightly grinding the sample with an agate mortar and pestle, the sample is loaded into a sample holder for the x-ray powder diffraction measurement. The x-ray powder diffraction patterns are measured using a Siemens D5000 x-ray powder diffractometer equipped with a CuKα source (λ=l .54056A). Forms H and HI have typical XRD patterns as represented in Tables 1 and 2, respectively, with peaks which have typical relative intensities (I/I0) at the following 2Θ values, where θ is the incident angle of the X-ray beam.. The error of measurement is +/- 0.2° in 2Θ. X-ray peaks with I I0 of 5% or greater were reported in Tables 1 and 2. The cutoff was chosen arbitrarily. -1-
Form H; Table 1
Form HI; Table 2
It is well known in the crystallography art that, for any given crystal form, the relative intensities of the diffraction peaks may vary due to a number of factors, including the effects of preferred orientation which result from a particular crystal morphology, and particle size. Where the effects of preferred orientation and or particle size are present, peak intensities (that is, the I/ o value) are altered, but the characteristic peak positions of the polymorph are unchanged. See, e.g., The United States Pharmacopoeia #23, National Formulary #18, pages 1843-1844, 1995. The effects of preferred orientation can be greatly reduced using a sample that is prepared in a manner that minimizes these effects, such as the use of a well ground sample.
Form H may be characterized as having an X-ray diffraction pattern which comprises peaks at the following 2Θ values: 6.0, 9.1, 10.8, 11.6, 12.0, 13.1, 13.6, 24.1, and 26.2 + 0.2° when measured using a copper radiation source. Form HI may be characterized as having an X-ray diffraction pattern which comprises peaks at the following 2Θ values: 8.2, 10.4, 11.9, 17.2, and 23.0 ± 0.2° when measured using a copper radiation source.
Additionally, as the skilled artisan would appreciate, Form H and Form HI may also be characterized by solid state NMR spectroscopy. Solid state ^C NMR spectra were collected with a Varian Unity 400 MHz spectrometer operating at a carbon frequency of 100.580 MHz, using high-power proton decoupling, cross polarization (CP) and magic angle spinning (MAS) at -7.0 kHz. Acquisition parameters were as follows: 90° proton r.f. pulse width 4.0 μs, contact time 1.0 ms, pulse repetition time 5 s, spectral width 50 kHz, and acquisition time 50 ms. Chemical shifts, expressed as parts per million, were referenced to the methyl group of hexamethylbenzene (δ = 17.3 ppm) by sample replacement. The magic angle was adjusted by optimizing the sidebands of the
Br signal of KBr as described by Frye and Maciel (Frye J. S. and Maciel G. E., J. Magn. Reson., 1982, 48, 125). Form H has a solid-state 13C NMR spectrum comprised of isotropic peaks at the following chemical shifts: 29.9, 50.1, 55.3, 62.0, 66.5, 72.0, 75.8, 104.8, 107.5, 108.2, 109.1, 110.2, 112.0, 118.4, 119.5, 120.1, 123.1, 128.7, 131.1, 133.0, 134.8, 136.4, 136.9, 139.9, 140.0, 142.3, 144.5, 146.6, 149.0, 144.2, 153.0 and 153.6 ppm.
Form HI has a solid-state 13C NMR spectrum comprised of isotropic peaks at the following chemical shifts: 30.3, 50.4, 59.1, 63.2, 72.8, 77.2, 109.1, 110.2, 112.2, 112.8,
118.7, 119.5, 119.9, 121.0, 122.2, 123.0, 128.9, 130.6, 132.7, 134.0, 136.4, 140.0, 141.0,
141.8, 142.5, 143.3, 146.1, 153.1, 153.8 and 154.7 ppm.
Table 3; Chemical Shift Data and Peak Assignments for the Crystal Forms.
Additionally, as the skilled artisan would appreciate, Form H and Form HI may also be characterized by the molar ratio of the chloride anion in the present invention. The determination can be analyzed by ion chromatography using a Dionex HPIC-AS4 with a Dionex Anion AMMS-1 micro-membrane suppressor. Using a standard stock solution of anhydrous sodium chloride (16.5 mg/100 ml), with standard concentration ranges form 50-150% of the chloride anion. The sample was prepared in a lmg/ml solution of purified water. Sonication for 10-15 min. and filtration was applied if insolubility was seen. A typical sample concentration of 0. lmg/ml was used. The HPLC analysis conditions were conducted at 2 ml/min at room temperature with a run time of 780 sec. An approximate retention time of the chloride anion is about 115 sec. The molar percent of the anion was calculated by the following data analysis. A least squares calibration curve of the standard peak versus the standard peak concentration (μg/ml).
Salt wt. (mg) Anion F.W. anion (μ g / mL) : -x- - x 1000 ( g / mg) x dilution
100 mL Salt F.W.
Determination of the anion concentration (μg/mL) in the sample solution was calculated from the observed peak area and the calibration curve. mL (samp, diluent) l g
% anion = (μ g anion/mL found*) [dilution] (100%) mg (samp, weight) 11000 // gj *from calibration curve
The precise conditions under which Form H or Form HI is formed may be experimentally determined and it is only possible to give a number of methods, which have been found to be suitable in practice. Thus, for example, Form H may be prepared by slurry conversion of Form HI under controlled conditions. It is understood that the present process can utilize (2R)-α«tz-5-{3-[4-(10,l l-difluoromethanodibenzosuber-5- yl)piperazin-l-yl]-2-hydroxypropoxy} quinoline trihydrochloride regardless of its hydration state or crystalline state. In particular, it can be prepared from (2R)-αratt-5-{3- [4-(l 0, 11 -difluoromethanodibenzosuber-5-yl)piperazin-l -yl]-2- hydroxypropoxy} quinoline trihydrochloride. The skilled artisan is aware that it may be advantageous to add "seeds" of Form H or HI to the solution in order to induce crystallization. Form H or HI can be isolated from the crystallization solution by filtration, if desired after cooling, and washed and dried. If desired, either Form H or HI maybe further crystallized using similar conditions for crystallization, to those described below. The present invention is further illustrated by the following examples and preparations. These examples and preparations are illustrative only and are not intended to limit the invention in any way. (2R)-α«t/-l-[4-(10,l l-Difluoromethano-10,11-dihydro- 5H-dibenzo[a,d]cyclohepten-5-yl)-piperazin-l-yl]-3-quinolin-5-yloxy)-propan-2-ol trihydrochloride may be prepared by any number of different methods as described in the art, see e.g. WOOO/75121 and U.S. patent 5,654,304.
Example 1 Form HI Suspend (2R)-αntt-l-[4-(10,l l-difluoromethano-10,1 l-dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-piperazin-l-yl]-3-quinolin-5-yloxy)-propan-2-ol trihydrochloride (502 mg) in 3 A EtOH (10 mL). Heat to reflux and add H2O (5 mL) to dissolve the solids. Remove the heat source and add EtOAc (75 mL) to the warm solution. Isolate by vacuum filtration, wash with EtOAc (2 mL), and air-dry in a Bϋchner funnel under an air stream. Yield = 415 mg. Example 2 Form HI Suspend (2R)-α»Λ'-l-[4-(10,l l-difluoromethano-10,1 l-dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-piperazin-l-yl]-3-quinolin-5-yloxy)-propan-2-ol trihydrochloride (1.53 g) in 15 mL of 8.T IPA/H2O, heat the suspension under reflux for 10-15 minutes to effect dissolution of the solids, and allow the solution to cool to room temperature to precipitate Form HI. Allow the suspension to slurry overnight (-16 hrs), after which time isolate the solid product by vacuum filtration and wash with 10 mL IP A. Yield - 1.14 g.
Example 3 Form H Suspend 7.52 g of (2R)-αntt-l-[4-(10,l l-difluoromethano-10,1 l-dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-piperazin-l-yl]-3-quinolin-5-yloxy)-propan-2-ol trihydrochloride in 6: 1 v/v tert-butanol- water (75 mL) and heat under reflux for 30 minutes to dissolve the solids. Turn the heat source off, and allow the solution to slowly cool to room temperature. Observe a thick crystal slurry after 2 hours at 0 °C, collect the solids by vacuum filtration, wash with ethyl acetate (50 mL), air-dry for ~6 hours and then dry in a 70 °C convection oven for 65 hours. Yield = 5.33g.
Example 4 Form H Suspend (2R)-αnft"-l-[4-(10,l l-difluoromethano-10,1 l-dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-piperazin-l-yl]-3-quinolin-5-yloxy)-propan-2-ol trihydrochloride (506 mg) in 13 mL of 20:1 H°A/H2O and heat under reflux to dissolve the solids. Allow to cool to room temperature, during which time oily solid particles begin to precipitate from solution. Slurry the solid product for 24 hrs., and then isolate by vacuum filtration, wash with 5 mL PA and air dry. Yield = 310 mg. Example 5 Form H Dry Form HI at 50-70°C in a convection oven.
The present invention further provides a method of treatment for a drug resistant disease comprising coadministering to a mammal in need thereof a resistance modulating amount of the 2.5 salt, Form H, or Form HI and an effective amount of a treatment drug for said drug resistant disease. Preferably the disease is cancer. Preferably, the treatment drug is a cancer chemotherapeutic agent.
The present invention further provides a method of treatment for a multidrug resistant disease comprising coadministering to a mammal in need thereof a multidrug resistance modulating amount of the 2.5 salt, Form H, or Form HI and an effective amount of a treatment drug for said multidrug resistant disease. Preferably, the treatment drug is a cancer chemotherapeutic agent.
The present invention further provides a method for enhancing bioavailability of a pharmaceutically active agent to the brain, comprising coadministering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 salt, Form H, or Form HI sufficient enough to allow said drug to cross the blood-brain barrier and enter the brain. Preferable the active agent is an HIV protease inhibitor. Examples of such protease inhibitors contemplated by the present invention are NELFINAVIR, which is preferably administered as the mesylate salt at 750 mg three times per day (U.S. Patent No. 5,484,926, herein incorporated by reference); RITONAVIR, which is preferably administered at 600 mg twice daily (U.S. Patent No. 5,484,801, herein incorporated by reference); SAQUINAVIR, which is preferably administered at the mesylate salt at 1,200 mg three times per day (U.S. Patent No. 5,196,438, herein incorporated by reference); IND AVTR, which is preferably administered as the sulfate salt at 800 mg three times per day (U.S. Patent No. 5,413,999, herein incorporated by reference); and AMPRENAVIR, which is preferably administered at 1,200 mg twice daily (U.S. Patent No. 5,585,397, herein incorporated by reference). The skilled artisan would recognize that this list is not exhaustive. Additionally, the skilled artisan would recognize that the protease inhibitors' administration to a patient may vary from the preferred.
The present invention further provides the use of the 2.5 salt, Form H, or Form HI in combination with an effective amount of a treatment drug, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a drug resistant disease. Preferably the disease is cancer. Preferably, the treatment drug is a cancer chemotherapeutic agent.
The invention further provides the use of the 2.5 salt, Form H, or Form HI in combination with an effective amount of a treatment drug, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a multidrug resistant disease. Preferably, the treatment drug is a cancer chemotherapeutic agent.
The present invention further provides the use of the 2.5 salt, Form H, or Form HI in combination with a pharmaceutically active agent, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for enhancing bioavailability of the pharmaceutically active agent to the brain, comprising coadministering to a mammal in need thereof a therapeutically effective amount of said drug and the 2.5 salt, Form H, or
Form HI sufficient enough to allow said drug to cross the blood-brain barrier and enter the brain. Preferably, the active agent is an HIV protease inhibitor. Preferably, the present invention relates to a pharmaceutical formulation comprising the 2.5 salt, Form H, or Form HI; one or more pharmaceutical carriers, diluents, or excipients; and optionally a treatment drug.
When employed as a pharmaceutical, the 2.5 salt, Form H, or Form HI is usually administered in the form of pharmaceutical compositions. These compositions can be administered by a variety of routes including oral, rectal, transdermal, and intranasal. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise the 2.5 salt, Form H, or Form HI.
The term "substantially pure" refers to the crystal phase purity of Form H or HI. In practice we have found that small amounts of other crystalline forms do not adversely affect the advantageous properties of Form H or HI. According to the present invention substantially pure refers to Form H or HI which is greater than 90%, preferably greater than 95% of the total crystalline material.
This invention also includes pharmaceutical compositions which contain the 2.5 salt, Form H, or Form HI (referred to as "active ingredient" herein below) associated with pharmaceutically acceptable carriers. In making the compositions of this invention, the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier, which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid or semi-solid, which acts as a vehicle, carrier, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, emulsions, aerosols, ointments containing, for example, up to 10% by weight of the active compound, tablet, soft and hard gelatin capsules, suppositories, and sterile packaged powders.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, algmates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 mg to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Preferably, the 2.5 salt, Form H, or Form HI is employed at no more than about 20 weight percent of the pharmaceutical composition, more preferably no more than about 15 weight percent, with the balance being pharmaceutically inert carrier(s).
The 2.5 salt, Form H, or Form HI is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. For preparing compositions such as tablets, the active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. , This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can separated by enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
Compositions for inhalation or insufflation include liquids, suspensions, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices, which deliver the formulation in an appropriate manner.
Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent
5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the. blood-brain barrier. One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Patent 5,011,472, which is herein incorporated by reference.
Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions, which can transiently open the blood-brain barrier.
Other suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).
As noted above, the 2.5 salt, Form H, or Form HI is suitable for use in a variety of drug delivery systems described above. Additionally, in order to enhance the in vivo serum half-life of the present compound, it may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques maybe employed which provide an extended serum half-life of the compounds. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., U.S. Patent Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference.
The amount of the 2.5 salt, Form H, or Form HI administered to the patient will vary depending upon the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions are administered to a patient already suffering from cancer in an amount sufficient to at least partially arrest further onset of the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the degree or severity of the disease state in the patient, the age, weight and general condition of the patient, and the like. Preferably, for use as therapeutics, the 2.5 salt, Form H, or Form HI is administered at dosages ranging from about 1 to about 500 mg/kg/day.
The present invention provides a process for preparing the Form H or Form HI which comprises crystallizing (2R)-α«tt-5-{3-[4-(10,l l-difluoromethanodibenzosuber-5- yl)piperazin- 1 -yl] -2-hydroxypropoxy} quinoline trihydrochloride from a solution of water and a water miscible solvent under conditions which yield Form H or HI.

Claims

We Claim:
1. A compound of the formula: (2R)-α«t/-5-{3-[4-(10,l 1- difluoromethanodibenzosuber-5-yl)piperazin-l-yl]-2-hydroxypropoxy}quinoline 2.5 hydrochloride.
2. Crystalline (2R)-αntt-5-{3-[4-(10,l l-difluoromethanodibenzosuber-5- yl)piperazin-l-yl] -2-hydroxypropoxy} quinoline 2.5 hydrochloride, "Form H," having an X-ray diffraction pattern comprising peaks at the following 2Θ values: 6.0, 9.1, 10.8, 11.6, 12.0, 13.1, 13.6, 24.1, and 26.2 + 0.2° when measured using a copper radiation source.
3. Crystalline (2R)-anti-5- {3-[4-(l 0, 11 -difluoromethanodibenzosuber-5- yl)piperazin-l-yl]-2-hydroxypropoxy}quinoline 2.5 hydrochloride, "Form HI," having an X-ray diffraction pattern comprising peaks at the following 2Θ values: 8.2, 10.4, 11.9, 17.2, and 23.0 ± 0.2° when measured using a copper radiation source.
4. A pharmaceutical formulation comprising the compound of Claim 1, 2, or 3; one or more pharmaceutical carriers, diluents, or excipients; and optionally a treatment drug.
5. A method of treatment for a drug resistant disease comprising coadministering to a mammal in need thereof a resistance modulating amount the compound of Claim 1, 2, or 3 and an effective amount of a treatment drug for said drug resistant disease.
6. The method of Claim 5, wherein the disease is cancer.
7. The method of Claim 5 or Claim 6 wherein the treatment drug is a cancer chemotherapeutic agent.
8. A method of treatment for a multidrug resistant disease comprising coadministering to a mammal in need thereof a multidrug resistance modulating amount of the compound of Claim 1, 2, or 3 and an effective amount of a treatment drug for said multidrug resistant disease.
9. The method of Claim 8 wherein the treatment drug is a cancer chemotherapeutic agent.
10. A method for enhancing bioavailability of a pharmaceutically active agent to the brain, comprising coadministering to a mammal in need thereof a therapeutically effective amount of said drug and the compound of Claim 1, 2, or 3 sufficient enough to allow said drug to cross the blood-brain barrier and enter the brain.
11. A method for enhancing oral bioavailability of a drug comprising administering to a mammal in need thereof a therapeutically effective amount of said drag and the compound of Claim 1, 2, or 3; sufficient enough to allow said drug to be transported across the gastrointestinal tract and enter the bloodstream.
EP02723495A 2001-04-25 2002-04-12 Novel salt and crystalline forms of (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinoline Expired - Lifetime EP1387683B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28655601P 2001-04-25 2001-04-25
US286556P 2001-04-25
US31881501P 2001-09-13 2001-09-13
US318815P 2001-09-13
PCT/US2002/008256 WO2002087581A1 (en) 2001-04-25 2002-04-12 Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline

Publications (2)

Publication Number Publication Date
EP1387683A1 true EP1387683A1 (en) 2004-02-11
EP1387683B1 EP1387683B1 (en) 2005-02-09

Family

ID=26963904

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02723495A Expired - Lifetime EP1387683B1 (en) 2001-04-25 2002-04-12 Novel salt and crystalline forms of (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinoline

Country Status (9)

Country Link
US (2) US7282585B2 (en)
EP (1) EP1387683B1 (en)
JP (1) JP2004527552A (en)
AT (1) ATE288754T1 (en)
CA (1) CA2442608A1 (en)
DE (1) DE60202944T2 (en)
ES (1) ES2236506T3 (en)
PT (1) PT1387683E (en)
WO (1) WO2002087581A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248145B2 (en) 2008-04-09 2022-02-15 Zephyros, Inc. Structural adhesives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
TWI267511B (en) 1999-06-03 2006-12-01 Lilly Co Eli Process for preparing 10,11-methanobenzosuberane derivatives
JP2003501425A (en) 1999-06-03 2003-01-14 イーライ・リリー・アンド・カンパニー Method for producing 10,11-methanodibenzosuberane derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02087581A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248145B2 (en) 2008-04-09 2022-02-15 Zephyros, Inc. Structural adhesives

Also Published As

Publication number Publication date
WO2002087581A1 (en) 2002-11-07
CA2442608A1 (en) 2002-11-07
US20070244124A1 (en) 2007-10-18
US7582762B2 (en) 2009-09-01
EP1387683B1 (en) 2005-02-09
PT1387683E (en) 2005-06-30
ATE288754T1 (en) 2005-02-15
ES2236506T3 (en) 2005-07-16
DE60202944D1 (en) 2005-03-17
DE60202944T2 (en) 2006-03-23
US20040097519A1 (en) 2004-05-20
JP2004527552A (en) 2004-09-09
US7282585B2 (en) 2007-10-16

Similar Documents

Publication Publication Date Title
EP2872474B1 (en) Anthraquinone analogs and methods of making and using thereof
CA2946899C (en) Naphthofuran compounds and compositions for targeting cancer stem cells
EP2547205B1 (en) Novel methods for targeting cancer stem cells
CN104016951B (en) Compounds and compositions targeting cancer stem cells
CN115504976A (en) Adagrasib crystal form and preparation method thereof
KR20150129679A (en) Crystalline forms of [[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino]-acetic acid
US20200165190A1 (en) Amorphous Form of Vilanterol Trifenatate and Processes for the Preparation Thereof
JP2024532814A (en) Impurities in plinabulin or its preparations and their uses
WO2021143954A2 (en) Crystalline form of fluvatinib or fluvatinib methanesulfonate and preparation method therefor
US7582762B2 (en) Salt and crystalline forms of (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-YL)piperazin-1-YL]-2-hydroxypropoxy}quinoline
CN112135813A (en) Crystalline form of S-apomorphine
EP4176903A1 (en) Drug-clay mineral complex containing phospholipid and oral administration composition including same
CN107141284B (en) Coptisine analog derivative, preparation method, pharmaceutical composition and anticancer usage
JP2002510702A (en) Form VI of 6,6-dichloro-2- (isopropylamino) -1- (β-L-ribofuranosyl) -1H-benzimidazole
WO2024059607A1 (en) Physical forms of an inhibitor of prc2
EP2736334B1 (en) Denibulin di-hydrochloride
US6521755B1 (en) Process for preparing 10,11-methanobenzosuberane derivatives
CN113045554A (en) Fexotinib crystal form and preparation method thereof
JP7671362B2 (en) Pharmaceutical compositions, their preparation and use
CN105367622B (en) A kind of argatroban compound
CN114681465B (en) Lobaplatin-flavonoid drug cocrystal and preparation method and application thereof
CN114685492A (en) TAS-116 crystal form, preparation method, pharmaceutical composition and application thereof
WO2022256550A1 (en) Crystalline forms of an adenosine a2b receptor antagonist
EP4653441A1 (en) Salt of antidepressant compound, and preparation method therefor, pharmaceutical composition containing same and use thereof
CN118420586A (en) Dihydroquercetin and picolinic acid cocrystal, preparation method, pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REF Corresponds to:

Ref document number: 60202944

Country of ref document: DE

Date of ref document: 20050317

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20050401241

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20050420

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2236506

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

ET Fr: translation filed
26N No opposition filed

Effective date: 20051110

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: ELI LILLY AND COMPANY

Free format text: ELI LILLY AND COMPANY#LILLY CORPORATE CENTER#INDIANAPOLIS, INDIANA 46285 (US) -TRANSFER TO- ELI LILLY AND COMPANY#LILLY CORPORATE CENTER#INDIANAPOLIS, INDIANA 46285 (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20090316

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20090415

Year of fee payment: 8

Ref country code: ES

Payment date: 20090508

Year of fee payment: 8

Ref country code: IE

Payment date: 20090420

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20090415

Year of fee payment: 8

Ref country code: DE

Payment date: 20090409

Year of fee payment: 8

Ref country code: FI

Payment date: 20090416

Year of fee payment: 8

Ref country code: FR

Payment date: 20090417

Year of fee payment: 8

Ref country code: IT

Payment date: 20090421

Year of fee payment: 8

Ref country code: LU

Payment date: 20090424

Year of fee payment: 8

Ref country code: NL

Payment date: 20090405

Year of fee payment: 8

Ref country code: PT

Payment date: 20090403

Year of fee payment: 8

Ref country code: SE

Payment date: 20090407

Year of fee payment: 8

Ref country code: TR

Payment date: 20090319

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090422

Year of fee payment: 8

Ref country code: MC

Payment date: 20090330

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20090416

Year of fee payment: 8

Ref country code: CY

Payment date: 20090331

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090408

Year of fee payment: 8

BERE Be: lapsed

Owner name: *ELI LILLY AND CY

Effective date: 20100430

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20101101

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100412

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20101230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101103

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101012

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100503

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20110712

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100412